Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 87 | 2 | 84 | −1 |
| Shares | 28.2M | 1.68M | 30.8M | +4.25M (+16.0%) |
| Value | $316.6M | $18.9M | $219.7M | −$78.0M (−26.2%) |
2 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Carlyle Group Inc. | 2,935,106 | $20.9M | 0.62% |
| Simplify Asset Management Inc. | 237,935 | $1.70M | 0.30% |
| Silverarc Capital Management, LLC | 200,000 | $1.43M | 0.64% |
| UBS Oconnor LLC | 100,093 | $714.7K | 0.02% |
| Atom Investors LP | 86,607 | $618.4K | 0.34% |
| Millennium Management LLC | 57,863 | $413.0K | 0.00% |
| Marshall Wace, LLP | 37,096 | $264.9K | 0.00% |
| Simplex Trading, LLC | 29,411 | $209.0K | 0.01% |
| Two Sigma Investments, LP | 29,100 | $207.8K | 0.00% |
| Creative Planning | 20,000 | $142.8K | 0.00% |
| Belvedere Trading LLC | 13,525 | $96.6K | 0.04% |
| Stratos Wealth Advisors, LLC | 12,500 | $89.3K | 0.01% |
| Point72 Asset Management, L.P. | 11,505 | $82.1K | 0.00% |
| SG Americas Securities, LLC | 11,328 | $81.0K | 0.00% |
| Wells Fargo & Company | 4,726 | $33.7K | 0.00% |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 2,141 | $15.3K | 0.00% |
| Cubist Systematic Strategies, LLC | 1,649 | $11.8K | 0.00% |
Sold out (18)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Rhenman & Partners Asset Management AB | 235,210 | $2.64M |
| Walleye Capital LLC | 145,870 | $1.64M |
| SEI Investments Co | 58,585 | $657.3K |
| Two Sigma Advisers, LP | 14,800 | $166.1K |
| Squarepoint Ops LLC | 12,296 | $138.0K |
| AQR Capital Management LLC | 10,046 | $112.7K |
| Quantbot Technologies LP | 2,927 | $32.8K |
| U.S. Capital Wealth Advisors, LLC | 1,000 | $11.2K |
| UBS Group AG | 795 | $8.92K |
| US Bancorp | 349 | $3.92K |
| Quadrant Capital Group LLC | 212 | $2.38K |
| Massmutual Trust Co FSB | 160 | $2.00K |
| Lindbrook Capital, LLC | 159 | $1.78K |
| Whittier Trust Co | 33 | $369 |
| Parallel Advisors, LLC | 29 | $325 |
| Signaturefd, LLC | 24 | $269 |
| Rockefeller Capital Management L.P. | 29 | $0 |
| IFP Advisors, Inc | 6 | – |
Not filed for Q1 2023 yet (2)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Abingworth LLP | 1,435,106 | $16.1M |
| Rothschild & Co Asset Management US Inc. | 245,658 | $2.76M |